現在、価格および在庫状況を閲覧できません。
manufacturer/tradename
BPS Bioscience
technique(s)
activity assay: suitable (Fluorescence Polarization)
UniProt accession no.
shipped in
dry ice
storage temp.
-65 to -96°C
General description
The PDE1A Assay Kit is designed for identification of PDE1A inhibitors using fluorescence polarization. The assay is based on the binding of a fluorescent nucleotide monophosphate generated by PDE1A1 to the binding agent. The key to the PDE1A Assay Kit is the specific binding agent. Using this kit, only two simple steps on a microtiter plate are required for PDE1A reactions. First, the fluorescently labeled cAMP is incubated with a sample containing PDE1A1 for 1 hour. Second, a binding agent is added to the reaction mix to produce a change in fluorescent polarization. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.
Application
Study enzyme kinetics and screen small molecule inhibitors for drug discovery in high throughput screening (HTS) applications.Phosphodiesterases (PDEs) play an important role in the dynamic regulation of the second messengers cAMP (cyclic adenosine monophosphate) and cGMP (cyclic guanosine monophosphate) signaling, by hydrolyzing them. The PDE superfamily is composed of 11 families, with PDE4, 7 and 8 being cAMP-specific hydrolases, and thus regulating positive and negative responses to it. Among the 11 different families of PDEs, phosphodiesterase 1 (PDE1) sub-family of enzymes hydrolyze both cAMP and cGMP in a mutually competitive manner. The catalytic activity of PDE1 is stimulated by their binding to Ca2+/calmodulin, resulting in the integration of Ca2+ and cyclic nucleotide-mediated signaling in various diseases. The PDE1 family includes three subtypes, PDE1A, PDE1B and PDE1C, which differ for their relative affinities for cAMP and cGMP. These isoforms are differentially expressed throughout the body, including the cardiovascular, central nervous system and other organs. PDE1A increases vascular contraction of mesenteric arteries upon angiotensin II infusion in rats and also regulates cGMP hydrolysis in cardiomyocyte and vascular smooth muscle cells, which in turn controls smooth muscle tone. Inhibition of PDE1A attenuates adverse cardiac remodeling and may serve as a novel therapeutic approach to limit nitrate tolerance.
Datasheet and Protocols may be found here.
Datasheet and Protocols may be found here.
Features and Benefits
The PDE1A inhibitor screening assay kit comes in a convenient 96-well format, including purified PDE1A1 enzyme, fluorescently labeled PDE1A substrate (cAMP), binding agent, and PDE assay buffer for 100 enzyme reactions.
注意喚起語
Danger
ハザードコード
Hazard Classifications
Eye Dam. 1 - Skin Corr. 1B
保管分類
8A - Combustible corrosive hazardous materials
WGK
WGK 2
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Please refer to KIT Component information
pdsc
Please refer to KIT Component information
prtr
Please refer to KIT Component information
fsl
Please refer to KIT Component information
ishl_indicated
Please refer to KIT Component information
ishl_notified
Please refer to KIT Component information
cart
キットコンポーネントの情報を参照してください
jan
